Stories Related to Esai And Biogen, Leqembi Manufacturer, Receive Fda Approval For Alzheimer's Drug

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.       

Sections:  u.s.   
Topics:  Nevada   Washoe County   Reno   
RELATED ARTICLES
BING NEWS:
  • Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
    Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the race for breakthroughs.
    01/9/2025 - 7:36 pm | View Link
  • Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
    Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
    01/9/2025 - 4:24 pm | View Link
  • Eli Lilly's Alzheimer's treatment approved in China
    China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company ...
    12/17/2024 - 1:05 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More U.s. News